Product NDC: | 25021-670 |
Proprietary Name: | Cisatracurium Besylate |
Non Proprietary Name: | cisatracurium besylate |
Active Ingredient(s): | 2 mg/mL & nbsp; cisatracurium besylate |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 25021-670 |
Labeler Name: | Sagent Pharmaceuticals |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA201851 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120927 |
Package NDC: | 25021-670-10 |
Package Description: | 10 VIAL in 1 CARTON (25021-670-10) > 10 mL in 1 VIAL |
NDC Code | 25021-670-10 |
Proprietary Name | Cisatracurium Besylate |
Package Description | 10 VIAL in 1 CARTON (25021-670-10) > 10 mL in 1 VIAL |
Product NDC | 25021-670 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | cisatracurium besylate |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20120927 |
Marketing Category Name | ANDA |
Labeler Name | Sagent Pharmaceuticals |
Substance Name | CISATRACURIUM BESYLATE |
Strength Number | 2 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Neuromuscular Nondepolarizing Blockade [PE],Nondepolarizing Neuromuscular Blocker [EPC] |